Filing Details

Accession Number:
0001209191-20-039019
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-25 19:40:23
Reporting Period:
2020-06-23
Accepted Time:
2020-06-25 19:40:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1808158 Repare Therapeutics Inc. RPTX () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1765253 Versant Vantage I, L.p. One Sansome, Suite 3630
San Francisco CA 94104
No No Yes No
1777651 Versant Vantage I Gp, L.p. One Sansome, Suite 3630
San Francisco CA 94104
No No Yes No
1777653 Versant Vantage I Gp-Gp, Llc One Sansome, Suite 3630
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2020-06-23 2,054,198 $0.00 2,705,660 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 156,335 $0.00 205,915 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 68,398 $0.00 90,090 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 61,791 $0.00 81,387 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 2,443,883 $0.00 2,443,883 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 111,361 $0.00 2,817,021 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 8,475 $0.00 214,390 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 3,708 $0.00 93,798 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 3,350 $0.00 84,737 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 875,568 $0.00 3,319,451 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 458,282 $0.00 458,282 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-23 150,000 $20.00 608,282 No 4 P Indirect See Footnotes
Common Shares Acquisiton 2020-06-23 100,000 $20.00 3,419,451 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Class A Preferred Shares Disposition 2020-06-23 2,054,198 $0.00 2,054,198 $0.00
Common Shares Class A Preferred Shares Disposition 2020-06-23 156,335 $0.00 156,335 $0.00
Common Shares Class A Preferred Shares Disposition 2020-06-23 68,398 $0.00 68,398 $0.00
Common Shares Class A Preferred Shares Disposition 2020-06-23 61,791 $0.00 61,791 $0.00
Common Shares Class A Preferred Shares Disposition 2020-06-23 2,443,883 $0.00 2,443,883 $0.00
Common Shares Class B Preferred Shares Disposition 2020-06-23 111,361 $0.00 111,361 $0.00
Common Shares Class B Preferred Shares Disposition 2020-06-23 8,475 $0.00 8,475 $0.00
Common Shares Class B Preferred Shares Disposition 2020-06-23 3,708 $0.00 3,708 $0.00
Common Shares Class B Preferred Shares Disposition 2020-06-23 3,350 $0.00 3,350 $0.00
Common Shares Class B Preferred Shares Disposition 2020-06-23 875,568 $0.00 875,568 $0.00
Common Shares Class B Preferred Shares Disposition 2020-06-23 458,282 $0.00 458,282 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each Series A Preferred Share and each Series B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date.
  2. The securities are held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of the shares held by VVC V, except to the extent of its pecuniary interest therein.
  3. The securities are held by Versant Venture Capital V (Canada) LP ("VVC(Canada)"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). By virtue of such relationships, VV V (Canada) GP and VV V (Canada) may be deemed to have voting and investment power over the securities held by VVC V (Canada) and as a result may be deemed to have beneficial ownership over such securities. Each of VV V (Canada) and VV V (Canada) GP disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of its pecuniary interest therein.
  4. The securities are held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). VV V is the sole general partner of VOAF I and may be deemed to have voting and investment power over the securities held by VOAF I and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of the shares held by VOAF I, except to the extent of its pecuniary interest therein.
  5. The securities are held by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. VV V disclaims beneficial ownership of the shares held by VAF V, except to the extent of its pecuniary interest therein.
  6. The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. By virtue of such relationships, VV VI GP and VV VI may be deemed to have voting and investment power over the securities held by VVC VI and as a result may be deemed to have beneficial ownership over such securities. Each of VV VI GP and VV VI disclaims beneficial ownership of the shares held by VVC VI, except to the extent of its pecuniary interest therein.
  7. The securities are held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. By virtue of such relationships, VV I GP and VV I GP-GP may be deemed to have voting and investment power over the securities held by VV I and as a result may be deemed to have beneficial ownership over such securities. Each of VV I GP-GP and VV I GP disclaims beneficial ownership of the shares held by VV I, except to the extent of its pecuniary interest therein.
  8. These securities were purchased by VV I.
  9. These securities were purchased by VVC VI.